Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies.
Konstantinos PapamichaelAdam S CheifetzPublished in: Expert opinion on drug metabolism & toxicology (2022)
Recent advances in sampling, quantification, and support of clinical decisions include POC assays and PK dashboards, which may allow for prompt and precise application of TDM in clinical practice. Future perspectives toward a more personalized implementation of TDM could include the incorporation of pharmacogenetics/pharmacogenomics to identify subgroups of patients who would benefit more from proactive TDM or combination therapy such as those prone to immunogenicity and/or accelerated drug clearance. However, there are still challenges regarding the implementation of these innovative approaches, and more data from prospective studies and randomized controlled trials are needed.